Vaniqa Rx Facial Hair Remover May Be Strong OTC Switch Candidate

This article was originally published in The Rose Sheet

07 Aug 2000
News

The Rose Sheet

Executive Summary

Ongoing studies on Bristol-Myers Squibb's newly approved Vaniqa prescription hair removal drug could broaden the target consumer of the topical cream to include men. FDA approved the product for removal of women's facial hair July 27.

Already Registered? Sign in to continue reading.

New to HBW Insight? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

RS008300

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

RS008300

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Vaniqa Rx Facial Hair Remover May Be Strong OTC Switch Candidate

News

Executive Summary

Related Content

OTC Vaniqa Could Surface By Early 2005

OTC Vaniqa Could Surface By Early 2005

Vaniqa

Vaniqa

Gillette

Gillette Rx Vaniqa Deal May Be Anecdote To Hairy Third Quarter - Stock Index

Gillette Rx Vaniqa Deal May Be Anecdote To Hairy Third Quarter - Stock Index

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert